Figure 5.
Figure 5. Activity of B-B4–DM1 in a tumor xenograft model of human CD138+ MM. CB-17 SCID mice were inoculated subcutaneously in the interscapular area with 5 × 106 OPM1 (A-B) or OPM2 (C-D) MM cells. Mice were treated intravenously with B-B4–DM1 or control mAbs for 3 consecutive days. Tumor volume was assessed in 2 dimensions using an electronic caliper, and the volume was expressed in mm3 using the formula: V = 0.5a × b2, where a and b are the long and short diameters of the tumor, respectively. Tumor volume and survival were calculated as described in “Materials and methods.” * indicates that P value is related to the curve with ▪. (E-F) Mice bearing large OPM1 tumors (1309 ± 60 mm3) were treated intravenously with B-B4–DM1 (150 μg DM1/kg) for a total of 3 consecutive days. Figure shows a significant tumor regression 12 days following the beginning of treatment.

Activity of B-B4–DM1 in a tumor xenograft model of human CD138+ MM. CB-17 SCID mice were inoculated subcutaneously in the interscapular area with 5 × 106 OPM1 (A-B) or OPM2 (C-D) MM cells. Mice were treated intravenously with B-B4–DM1 or control mAbs for 3 consecutive days. Tumor volume was assessed in 2 dimensions using an electronic caliper, and the volume was expressed in mm3 using the formula: V = 0.5a × b2, where a and b are the long and short diameters of the tumor, respectively. Tumor volume and survival were calculated as described in “Materials and methods.” * indicates that P value is related to the curve with ▪. (E-F) Mice bearing large OPM1 tumors (1309 ± 60 mm3) were treated intravenously with B-B4–DM1 (150 μg DM1/kg) for a total of 3 consecutive days. Figure shows a significant tumor regression 12 days following the beginning of treatment.

Close Modal

or Create an Account

Close Modal
Close Modal